Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims. » Read More
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
CNBC's Meg Tirrell reports the latest on Mylan's EpiPen classification and rebate through Medicaid.
Mylan's share of revenue from EpiPen due to Medicare and Medicaid more than doubled from 2011-2015.
A report also found similar reductions in the uninsured rate in urban and rural areas under Obamacare.
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid.
Michael Neidorff, Centene Chairman and CEO, shares his take on Obamacare and the state of health care ahead of the presidential election.
Lori Swanson, Minnesota Attorney General, shares her take on the controversy surrounding Mylan's EpiPen price hike.
According to Bloomberg, Mylan may have misclassified its EpiPen product under certain Medicaid guidelines. CNBC's Dominic Chu reports the details. John Spallanzani, GFI Group chief macro strategist, and the "FMHR" traders weigh in.
Blood-testing firm Theranos withdrew its request for emergency clearance of a Zika-virus blood test, The Wall Street Journal reported.
Obamacare rates are 7 percent less in states with greater Medicaid eligibility, a new analysis says.
The inquiry relates to people who are eligible for Medicare and Medicaid.
A dramatic drop in the uninsured rate nationally has not been matched in states that did not expand Medicaid.
Lifetime medical-care costs can average $245,000 for a 65-year-old couple, so it's important to factor in health costs when saving.
Three people were charged with conspiring with others to have unqualified people admitted to skilled nursing homes and assisted living facilities.
The 19 states that have not expanded Medicaid have seen less dramatic reductions in uninsured rates than expansion states.
U.S. regulators have banned Elizabeth Holmes, the chief executive of Theranos, from owning or operating a laboratory for at least two years.